B−81/100
Desk Score
Dispatch #6Editorial
Ro
A heavyweight platform with brand-name access — but opaque compounded pricing clouds its dispatch.
Visit Ro ↗Editorial — no commercial relationship.
- Semaglutide
- Not disclosed
- Tirzepatide
- Not disclosed
- Coverage
- Multi-state
- Brand-name
- Yes
Desk Score breakdown
Each of the six scored dimensions. See the methodology.
Price transparency62/100
State access84/100
Molecule range88/100
Onboarding speed78/100
Support responsiveness82/100
Licensing & trust84/100
What the Desk likes
- Brand-name access and insurance navigation
- Oral options available
- Well-funded, stable platform
Where points come off
- Compounded pricing not disclosed up front
- Premium positioning limits price transparency score
The Desk's briefing — B−
Best for: Patients who want brand-name capability and insurance navigation support.
Pricing and verification reflect Ro's public disclosures at last scoring; the Desk Score is our editorial judgment per the methodology. Prices change — confirm on Ro's site. Not medical advice; see our disclosure.